Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Expert Ratings for Rubius Therapeutics

Over the past 3 months, 5 analysts have published their opinion on Rubius Therapeutics (NASDAQ:RUBY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 2 0 3 0 0
Last 30D 2 0 2 0 0
1M Ago 0 0 0 0 0
2M Ago 0 0 1 0 0
3M Ago 0 0 0 0 0

These 5 analysts have an average price target of $6.4 versus the current price of Rubius Therapeutics at $2.405, implying upside.

Below is a summary of how these 5 analysts rated Rubius Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average has decreased by 67.68% from the previous average price target of $19.80.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Analyst Ratings: What Are They?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.